Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitoxantrone hydrochloride liposome (CSPC Pharmaceutical Group, 045f15)
- Development stage
- Unknown
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Mitoxantrone hydrochloride liposome is a liposomal formulation of the synthetic anthracenedione cytotoxic agent mitoxantrone. It acts as a DNA intercalator and a topoisomerase II inhibitor, leading to DNA strand breaks and inhibition of DNA synthesis. The liposomal encapsulation is designed to improve the pharmacokinetic profile, enhance tumor targeting via the enhanced permeability and retention (EPR) effect, and reduce systemic toxicities, particularly the cardiotoxicity associated with conventional mitoxantrone. Developed by CSPC Pharmaceutical Group, it was first approved in China (under the brand name Duoenda) for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL). It is also being investigated for various solid tumors and other hematologic malignancies.
- Brand names
- Duoenda
- Other names
- mitoxantrone hydrochloride liposomal injectionmitoxantrone hydrochloride liposome injectionmitoxantrone liposomal
02
Targets
DNATOP2B (DNA topoisomerase II beta)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on mitoxantrone hydrochloride liposome (CSPC Pharmaceutical Group, 045f15).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitoxantrone hydrochloride liposome (CSPC Pharmaceutical Group, 045f15).